Takeda: Primary Endpoint Not Achieved In Orteronel Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
Japan’s Takeda announced on July 26 that the primary endpoint in Phase III trials with their non-steroid androgen inhibitor orteronel was not achieved.
You may also be interested in...
GSK Aims To Launch 13 Blockbusters In Five Years
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month
France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports